Cited by 1,086SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesRespiratory viral infections research

The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Open access

Gupta, Anil, Gonzalez-Rojas, Yaneicy, Juarez, Erick, Crespo Casal, Manuel, Moya, Jaynier, Falci, Diego R., Sarkis, Elias, Solis, Joel, Zheng, Hanzhe, Scott, Nicola, Cathcart, Andrea L., Hebner, Christy M., Sager, Jennifer, Mogalian, Erik, Tipple, Craig, Peppercorn, Amanda, Alexander, Elizabeth, Pang, Phillip S., Free, Almena, Brinson, Cynthia, Aldinger, Melissa, Shapiro, Adrienne E.·2021·New England Journal of Medicine

DOI 10.1056/nejmoa2107934

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Coronavirus disease 2019 (Covid-19) disproportionately results in hospitalization or death in older patients and those with underlying conditions. Sotrovimab is a pan-sarbecovirus monoclonal antibody that was designed to prevent progression of Covid-19 in high-risk patients early in the course of disease. METHODS: In this ongoing, multicenter, double-blind, phase 3 trial, we randomly assigned, in a 1:1 ratio, nonhospitalized patients with symptomatic Covid-19 (≤5 days after the onset of symptoms) and at least one risk factor for disease progression to receive a single infusion of sotrovimab at a dose of 500 mg or placebo. The primary efficacy outcome was hospitalization (for >24 hours) for any cause or death within 29 days after randomization. RESULTS: In this prespecified interim analysis, which included an intention-to-treat population of 583 patients (291 in the sotrovimab group and 292 in the placebo group), 3 patients (1%) in the sotrovimab group, as compared with 21 patients (7%) in the placebo group, had disease progression leading to hospitalization or death (relative risk reduction, 85%; 97.24% confidence interval, 44 to 96; P = 0.002). In the placebo group, 5 patients were admitted to the intensive care unit, including 1 who died by day 29. Safety was assessed in 868 patients (430 in the sotrovimab group and 438 in the placebo group). Adverse events were reported by 17% of the patients in the sotrovimab group and 19% of those in the placebo group; serious adverse events were less common with sotrovimab than with placebo (in 2% and 6% of the patients, respectively). CONCLUSIONS: Among high-risk patients with mild-to-moderate Covid-19, sotrovimab reduced the risk of disease progression. No safety signals were identified. (Funded by Vir Biotechnology and GlaxoSmithKline; COMET-ICE ClinicalTrials.gov number, NCT04545060.).

Integrity signals

Registry

Crossref · 10.1056/nejmoa2107934

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884
A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study
Petrilli, C. M., Jones, S. A., Yang, J., Rajagopalan, H., O’Donnell, L., Chernyak, Y., Tobin, K. A., Cerfolio, R. J., François, F., & Horwitz, L. I. (2020) · BMJ · doi:10.1136/bmj.m1966 · Cited by 3,045
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020
CDC COVID-19 Response Team, CDC COVID-19 Response Team, Bialek, S. R., Boundy, E. O., Bowen, V. B., Chow, N. A., Cohn, A. C., Dowling, N. F., Ellington, S., Gierke, R., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6912e2 · Cited by 2,278
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19
Weinreich, D. M., Sivapalasingam, S., Norton, T., Ali, S., Gao, H., Bhore, R., Musser, B. J., Soo, Y., Rofail, D., Im, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035002 · Cited by 1,642
Development and Validation of a Clinical Risk Score to Predict the Occurrence of Critical Illness in Hospitalized Patients With COVID-19
Liang, W., Liang, H., Ou, L., Chen, B., Chen, A., Li, C., Li, Y., Guan, W., Sang, L., Lu, J., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.2033 · Cited by 1,387
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
Chen, P., Nirula, A., Heller, B., Gottlieb, R. L., Boscia, J., Morris, J., Huhn, G., Cardona, J., Mocherla, B., Stosor, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2029849 · Cited by 1,282
Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies
Chen, R. E., Zhang, X., Case, J. B., Winkler, E. S., Liu, Y., VanBlargan, L. A., Liu, J., Errico, J. M., Xie, X., Suryadevara, N., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01294-w · Cited by 881

Flagged first, then by citations

Show all 25 references

Sorted by citations

Items 301–400 of 1,000

The Data and Safety Monitoring Board: The Toughest Job in Clinical Trials
Evans, S. R., Zeng, L., & Dai, W. (2023) · NEJM Evidence · doi:10.1056/evidctw2200220 · Cited by 15
The Impact of Nirmatrelvir-Ritonavir in Reducing Hospitalizations Among High-Risk Patients With SARS-CoV-2 During the Omicron Predominant Era
Al‐Obaidi, M. M., Gungor, A. B., Murugapandian, S., Thajudeen, B., Mansour, I. S. M., Wong, R. C., Tanrıöver, B., & Zangeneh, T. T. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.02.022 · Cited by 15
Early and fair COVID-19 outcome risk assessment using robust feature selection
Giuste, F., He, L., Lais, P. F., Shi, W., Zhu, Y., Hornback, A. M., Tsai, C., Isgut, M., Anderson, B. J., & Wang, M. D. (2023) · Scientific Reports · doi:10.1038/s41598-023-36175-4 · Cited by 17
Deciphering Fc-effector functions against SARS-CoV-2
Beaudoin-Bussières, G., & Finzi, A. (2024) · Trends in Microbiology · doi:10.1016/j.tim.2024.01.005 · Cited by 19
Deciphering a reliable synergistic bispecific strategy of rescuing antibodies for SARS-CoV-2 escape variants, including BA.2.86, EG.5.1, and JN.1
Tong, Z., Tong, J., Lei, W., Xie, Y., Cui, Y., Jia, G., Li, S., Zhang, Z., Cheng, Z., Xing, X., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114338 · Cited by 15
Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) Infection
Al‐Obaidi, M. M., Gungor, A. B., Nematollahi, S., Zangeneh, T. T., Bedrick, E. J., Johnson, K. M., Low-Adegbija, N. E., Alam, R., Rangan, P., Heise, C. W., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac186 · Cited by 15
Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials
Farhangnia, P., Dehrouyeh, S., Safdarian, A. R., Farahani, S. V., Gorgani, M., Rezaei, N., Akbarpour, M., & Delbandi, A. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108786 · Cited by 14
Adverse Audio-Vestibular Effects of Drugs and Vaccines Used in the Treatment and Prevention of COVID-19: A Review
Skarzynska, M. B., Matusiak, M., & Skarzynski, P. H. (2022) · Audiology Research · doi:10.3390/audiolres12030025 · Cited by 15
Immunosuppressant Therapies in COVID-19: Is the TNF Axis an Alternative?
Palacios, Y., & Chávez‐Galán, L. (2022) · Pharmaceuticals · doi:10.3390/ph15050616 · Cited by 15
In vivo biodistribution and pharmacokinetics of sotrovimab, a SARS-CoV-2 monoclonal antibody, in healthy cynomolgus monkeys
Aweda, T. A., Cheng, S., Lenhard, S. C., Sepp, A., Skedzielewski, T., Hsu, C., Marshall, S., Haag, H., Kehler, J. R., Jagdale, P., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-06012-3 · Cited by 15
Early Treatment with Monoclonal Antibodies or Convalescent Plasma Reduces Mortality in Non-Vaccinated COVID-19 High-Risk Patients
Thümmler, L., Lindemann, M., Horn, P. A., Lenz, V., Konik, M., Gäckler, A., Boss, K., Theodoropoulos, F., Besa, V., Taube, C., et al. (2022) · Viruses · doi:10.3390/v15010119 · Cited by 15
Early report on the severity of COVID ‐19 in hematologic patients infected with the SARS‐CoV2 omicron variant
Ullrich, F., Hanoun, C., Turki, A. T., Liebregts, T., Breuckmann, K., Alashkar, F., Reinhardt, H. C., von Tresckow, B., & von Tresckow, J. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13818 · Cited by 15
Impact of anti‐SARS‐CoV‐2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective study
Assanto, G. M., Rocco, A. D., Malfona, F., Capriata, M., Giudice, I. D., Petrucci, L., Girardi, P., D’Elia, G. M., Martelli, M., Gentile, G., et al. (2022) · Hematological Oncology · doi:10.1002/hon.3113 · Cited by 14
SARS-CoV-2 neutralizing antibody bebtelovimab – a systematic scoping review and meta-analysis
Liew, M. N. Y., Kua, K. P., Lee, S. W. H., & Wong, K. K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1100263 · Cited by 14
K-Means Clustering Identifies Diverse Clinical Phenotypes in COVID-19 Patients: Implications for Mortality Risks and Remdesivir Impact
García‐Vidal, C., Teijón‐Lumbreras, C., Aiello, T. F., Chumbita, M., Menéndez, R., Mateu-Subirà, A., Peyrony, O., Monzó, P., Lopera, C., Gallardo‐Pizarro, A., et al. (2024) · Infectious Diseases and Therapy · doi:10.1007/s40121-024-00938-x · Cited by 14
Lessons from the Use of Monoclonal Antibodies to SARS-CoV-2 Spike Protein During the COVID-19 Pandemic
Casadevall, A., & Focosi, D. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-061323-073837 · Cited by 16
Molecular Modeling Predicts Novel Antibody Escape Mutations in the Respiratory Syncytial Virus Fusion Glycoprotein
Beach, S. S., Hull, M. A., Ytreberg, F. M., Patel, J. S., & Miura, T. A. (2022) · Journal of Virology · doi:10.1128/jvi.00353-22 · Cited by 14
Comparative Pharmacokinetics of Tixagevimab/Cilgavimab ( AZD7442 ) Administered Intravenously Versus Intramuscularly in Symptomatic SARS‐CoV ‐2 Infection
Ignacio, R. B., Wohl, D. A., Arends, R., Reddy, V. P., Mu, Y., Javan, A. C., Hughes, M. D., Eron, J. J., Currier, J. S., Smith, D. M., et al. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2706 · Cited by 14
Lessons from the frontline: The value of emergency care processes and data to pandemic responses across the Pacific region
Mitchell, R. D., O’Reilly, G. M., Herron, L., Phillips, G. A., Sharma, D., Brolan, C. E., Körver, S., Kendino, M., Poloniati, P., Kafoa, B., et al. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100515 · Cited by 14
Recent Developments in the Understanding of Immunity, Pathogenesis and Management of COVID-19
Yegiazaryan, A., Abnousian, A., Alexander, L. J., Badaoui, A., Flaig, B., Sheren, N., Aghazarian, A., Alsaigh, D., Amin, A., Mundra, A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23169297 · Cited by 14
B-cell malignancies and COVID-19: a narrative review
Luque-Paz, D., Sesques, P., Wallet, F., Bachy, E., & Ader, F. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.10.030 · Cited by 15
Real-world Evidence of the Effects of Novel Treatments for COVID-19 on Mortality: A Nationwide Comparative Cohort Study of Hospitalized Patients in the First, Second, Third, and Fourth Waves in the Netherlands
Slim, M. A., Appelman, B., Sengers, H. P., Dongelmans, D. A., de Keizer, N. F., Schade, R. P., de Boer, M. G. J., Müller, M. C. A., Vlaar, A. P. J., Wiersinga, W. J., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac632 · Cited by 14
The unmet need for COVID-19 treatment in immunocompromised patients
D’Abramo, A., Vita, S., & Nicastri, E. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07918-x · Cited by 14
AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants
Giesen, N., Busch, E., Schalk, E., Beutel, G., Rüthrich, M. M., Hentrich, M., Hertenstein, B., Hirsch, H. H., Karthaus, M., Khodamoradi, Y., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.11.030 · Cited by 14
Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial
Jagannathan, P., Chew, K. W., Giganti, M. J., Hughes, M. D., Moser, C., Main, M., Monk, P., Javan, A. C., Li, J. Z., Fletcher, C. V., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102250 · Cited by 14
Myeloid dysregulation and therapeutic intervention in COVID-19
Gu, R., Mao, T., Qiao, L., Su, T. T., & Wang, J. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101524 · Cited by 14
Referrals, access, and equity of monoclonal antibodies for outpatient COVID-19: A qualitative study of clinician perspectives
Hamer, M. K., Alasmar, A. Y., Kwan, B. M., Wynia, M. K., Ginde, A. A., & DeCamp, M. W. (2022) · Medicine · doi:10.1097/md.0000000000032191 · Cited by 13
Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2
Candel, F. J., Barreiro, P., Salavert, M., Cabello, A., Fernández‐Ruiz, M., Pérez‐Segura, P., Román, J. S., Berenguer, J., Córdoba, R., Delgado, R. B., et al. (2023) · Viruses · doi:10.3390/v15071449 · Cited by 14
Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trial
Png, M. E., Harris, V., Grabey, J., Hart, N. D., Jani, B., Butler, D., Carson‐Stevens, A., Coates, M., Cureton, L., Dobson, M., et al. (2024) · British Journal of General Practice · doi:10.3399/bjgp.2023.0444 · Cited by 13
Real World Experience with Regdanvimab Treatment of Mild-to-Moderate Coronavirus Disease-19 in a COVID-19 Designated Hospital of Korea
Hong, S. I., Ryu, B.-H., Hong, K., Bae, I., & Cho, O. (2022) · Infection and Chemotherapy · doi:10.3947/ic.2021.0143 · Cited by 13
Mortality in Severe Antibody Deficiencies Patients during the First Two Years of the COVID-19 Pandemic: Vaccination and Monoclonal Antibodies Efficacy
Milito, C., Cinetto, F., Palladino, A., Garzi, G., Punziano, A., Lagnese, G., Scarpa, R., Rattazzi, M., Pesce, A. M., Pulvirenti, F., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10051026 · Cited by 13
Treatment with sotrovimab for SARS-CoV-2 infection in a cohort of high-risk kidney transplant recipients
Villanego, F., Mazuecos, A., Cubillo, B. R., Merino, M. J., Poveda, I., Saura, I. M., Segurado, Ó., Vega, L. L. C., Eady, M., Zárraga, S., et al. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac177 · Cited by 13
Persistent Fever and Positive PCR 90 Days Post-SARS-CoV-2 Infection in a Rituximab-Treated Patient: A Case of Late Antiviral Treatment
Ertesvåg, N. U., Sakkestad, S. T., Zhou, F., Hoff, I., Kristiansen, T., Jonassen, T. M., Follesø, E., Brokstad, K. A., Dyrhovden, R., & Mohn, K. G.-I. (2022) · Viruses · doi:10.3390/v14081757 · Cited by 13
Spike-specific T-cell responses in patients with COVID-19 successfully treated with neutralizing monoclonal antibodies against SARS-CoV-2
Rotundo, S., Vecchio, E., Abatino, A., Giordano, C., Mancuso, S., Tassone, M. T., Costa, C., Russo, A., Trecarichi, E. M., Cuda, G., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.09.016 · Cited by 13
Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years
Remuzzi, G., Schiaffino, S., Santoro, M. G., FitzGerald, G. A., Melino, G., & Patrono, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.987816 · Cited by 16
Potent SARS-CoV-2 neutralizing antibodies with therapeutic effects in two animal models
Takeshita, M., Fukuyama, H., Kamada, K., Matsumoto, T., Makino‐Okamura, C., Uchikubo‐Kamo, T., Tomabechi, Y., Hanada, K., Moriyama, S., Takahashi, Y., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105596 · Cited by 13
Real-world effectiveness of casirivimab and imdevimab among patients diagnosed with COVID-19 in the ambulatory setting: a retrospective cohort study using a large claims database
Hussein, M. A., Wei, W., Mastey, V., Sanchez, R. J., Wang, D., Murdock, D. J., Hirshberg, B., Weinreich, D. M., & Jalbert, J. J. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-064953 · Cited by 13
Use and effectiveness of remdesivir for the treatment of patients with covid-19 using data from the Lean European Open Survey on SARS-CoV-2 infected patients (LEOSS): a multicentre cohort study
Pilgram, L., Appel, K. S., Ruethrich, M. M., Koll, C. E. M., Vehreschild, M. J. G. T., de Miranda, S. M. N., Hower, M., Hellwig, K., Hanses, F., Wille, K., et al. (2023) · Infection · doi:10.1007/s15010-023-01994-0 · Cited by 13
Efficacy of pre-exposure prophylaxis to prevent SARS-CoV-2 infection after lung transplantation: a two center cohort study during the omicron era
Gottlieb, J., Simon, S., Barton, J., Barnikel, M., Bachmann, M., Klingenberg, M.-S., Veit, T., & Kneidinger, N. (2023) · Infection · doi:10.1007/s15010-023-02018-7 · Cited by 13
The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysis
Glhoom, S., Fergany, A., El-Araby, D., Abdelkhalek, A. A., Gomaa, A., Zayed, E. O., & Abd‐ElGawad, M. (2024) · European journal of medical research · doi:10.1186/s40001-023-01549-x · Cited by 13
The fossilization of randomized clinical trials
Paneth, N. S., Joyner, M. J., & Casadevall, A. (2022) · Journal of Clinical Investigation · doi:10.1172/jci158499 · Cited by 13
Monoclonal Antibodies as Potential COVID-19 Therapeutic Agents
Plichta, J., Kuna, P., & Panek, M. (2022) · COVID · doi:10.3390/covid2050045 · Cited by 16
Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy
Gieselmann, L., DeLaitsch, A. T., Rohde, M., Gruell, H., Kreer, C., Ercanoglu, M. S., Gristick, H. B., Schommers, P., Ahmadov, E., Radford, C. E., et al. (2025) · Nature Immunology · doi:10.1038/s41590-025-02286-5 · Cited by 12
Allogeneic hematopoietic stem cell transplantation in the COVID-19 era
Bordat, J., Maury, S., & Leclerc, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1100468 · Cited by 13
Outcomes of targeted treatment in immunocompromised patients with asymptomatic or mild COVID-19: a retrospective study
Lahouati, M., Cazanave, C., Labadie, A. L., Gohier, P., Guirle, L., Desclaux, A., Gigan, M., Malvy, D. J.-M., Pedeboscq, S., Xuereb, F., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-42727-5 · Cited by 12
Preclinical and Clinical Investigations of Potential Drugs and Vaccines for COVID-19 Therapy: A Comprehensive Review With Recent Update
Mia, M. E., Howlader, M., Akter, F., & Hossain, M. M. (2024) · Clinical Pathology · doi:10.1177/2632010x241263054 · Cited by 12
Morbidity of SARS-CoV-2 in the evolution to endemicity and in comparison with influenza
Bartha, I., Maher, C., Lavrenko, V. P., Chen, Y.-P., Tao, Q., di Iulio, J., Boundy, K., Kinter, E. T., Yeh, W. W., Corti, D., et al. (2024) · Communications Medicine · doi:10.1038/s43856-024-00633-5 · Cited by 12
An Approach to the Treatment of Children With COVID-19
Boast, A., Curtis, N. C., Holschier, J., Purcell, R. A., Bannister, S., Plover, C., Chinnappan, M., Burgner, D. P., Boyce, S., McNab, S., et al. (2022) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003576 · Cited by 12
COVID-19 and Cancer: Special Considerations for Patients Receiving Immunotherapy and Immunosuppressive Cancer Therapies
Goldman, J. D., Gonzalez, M. A., Rüthrich, M. M., Sharon, E., & von Lilienfeld‐Toal, M. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_359656 · Cited by 12
Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID ‐19: The GIMEMA EMATO ‐0321 study
Marasco, V., Piciocchi, A., Candoni, A., Pagano, L., Guidetti, A., Musto, P., Bruna, R., Bocchia, M., Visentin, A., Turrini, M., et al. (2022) · British Journal of Haematology · doi:10.1111/bjh.18385 · Cited by 12
Fluvoxamine for the treatment of COVID-19
Nyirenda, J. L. Z., Sofroniou, M., Toews, I., Mikołajewska, A., Lehane, C., Monsef, I., Abu-Taha, A., Maun, A., Stegemann, M. S., & Schmucker, C. M. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015391 · Cited by 12
Comparative effectiveness of neutralising monoclonal antibodies in high risk COVID-19 patients: a Bayesian network meta-analysis
McConnell, D. J., Harte, M., Walsh, C., Murphy, D. M., Nichol, A., Barry, M. G., & Adams, R. (2022) · Scientific Reports · doi:10.1038/s41598-022-22431-6 · Cited by 12
SARS-CoV-2 variants of concern: a review
Sarkar, M. S., & Madabhavi, I. (2022) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2022.2337 · Cited by 14
Comparison of Preprint Postings of Randomized Clinical Trials on COVID-19 and Corresponding Published Journal Articles
Bai, A. D., Jiang, Y., Nguyen, D. L., Lo, C. K. L., Stefanova, I. Z., Guo, K., Wang, F., Zhang, C., Sayeau, K., Garg, A., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.53301 · Cited by 13
Oral anti‐viral therapy for early COVID ‐19 infection in patients with haematological malignancies: A multicentre prospective cohort
Minoia, C., Diella, L., Perrone, T., Loseto, G., Pelligrino, C., Attolico, I., Pasciolla, C., Totaro, V., Candia, M. S. D., Spada, V., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.18895 · Cited by 12
T cell control of SARS-CoV-2: When, which, and where?
Diniz, M. O., Maini, M. K., & Swadling, L. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101828 · Cited by 12
Sotrovimab Lowers the Risk of COVID ‐19 Related Hospitalization or Death in a Large Population Cohort in the United Arab Emirates
Sharif‐Askari, F. S., Alsayed, H. A. H., Tleyjeh, I. M., Sharif‐Askari, N. S., Hussain, A. A. S., Saddik, B. A., Hamid, Q. A., & Halwani, R. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2700 · Cited by 12
Circular RNAs as emerging regulators in COVID-19 pathogenesis and progression
Gao, X., Fang, D., Liang, Y., Deng, X., Chen, N., Min De, Z. E. N. G., & Luo, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.980231 · Cited by 13
Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19Preprint
Chew, K. W., Moser, C., Daar, E. S., Wohl, D. A., Li, J. Z., Coombs, R. W., Ritz, J., Giganti, M. J., Javan, A. C., Li, Y., et al. (2021) · medRxiv · doi:10.1101/2021.12.17.21268009 · Cited by 13
Pandora’s box: Paxlovid, prescribing, pharmacists and pandemic
Roberts, J. A., Duncan, A. J., & Cairns, K. A. (2022) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.1799 · Cited by 12
Kidney Transplant Recipients and Omicron: Outcomes, effect of vaccines and the efficacy and safety of novel treatmentsPreprint
Gleeson, S., Martin, P., Thomson, T., Thind, A. K., Prendecki, M. F., Spensley, K. J., Clarke, C., Roufosse, C. A., Pickard, G., Thomas, D., et al. (2022) · medRxiv · doi:10.1101/2022.05.03.22274524 · Cited by 12
An outpatient model of care for COVID ‐19 infected kidney transplant patients – The hospital‐at‐home
Liew, I. T., Tan, W. J. M., Ho, Q. Y., Chung, S. J., Thangaraju, S., Yong, J., Ng, E., He, X., Kwan, N., & Kee, T. Y. S. (2023) · Nephrology · doi:10.1111/nep.14155 · Cited by 11
Time from symptoms onset to remdesivir is associated with the risk of ICU admission: a multicentric analyses
Alonso-Navarro, R., Ramírez, M., Masiá, M., Paredes, R., Montejano, R., Povar-Echeverría, M., Carratalà, J., Salavert, M., Bernal, E., Dueñas, C., et al. (2023) · BMC Infectious Diseases · doi:10.1186/s12879-023-08222-y · Cited by 11
Vaccination and Antiviral Treatment Reduce the Time to Negative SARS-CoV-2 Swab: A Real-Life Study
VITO, A. D., Moi, G., Saderi, L., Puci, M. V., Colpani, A., Firino, L., Puggioni, A., Uzzau, S., Babudieri, S., Sotgiu, G., et al. (2023) · Viruses · doi:10.3390/v15112180 · Cited by 11
Integrating artificial intelligence-based epitope prediction in a SARS-CoV-2 antibody discovery pipeline: caution is warranted
Acar, D. D., Witkowski, W., Wejda, M., Wei, R., Desmet, T., Schepens, B., Cae, S. D., Sedeyn, K., Eeckhaut, H., Fijałkowska, D., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2023.104960 · Cited by 12
Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies
Inoue, T., Yamamoto, Y., Sato, K., Okemoto‐Nakamura, Y., Shimizu, Y., Ogawa, M., Onodera, T., Takahashi, Y., Wakita, T., Kaneko, M. K., et al. (2024) · iScience · doi:10.1016/j.isci.2024.109363 · Cited by 12
Clinical and molecular landscape of prolonged SARS-CoV-2 infection with resistance to remdesivir in immunocompromised patients
Iriyama, C., Ichikawa, T., Tamura, T., Takahata, M., Ishio, T., Ibata, M., Kawai, R., Iwata, M., Suzuki, M., Adachi, H., et al. (2025) · PNAS Nexus · doi:10.1093/pnasnexus/pgaf085 · Cited by 11
Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19
Shapiro, A. E., & Ignacio, R. B. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00762-3 · Cited by 12
Self-citation
Real-World Efficacy of Regdanvimab on Clinical Outcomes in Patients with Mild to Moderate COVID-19
Kim, T., Joo, D.-H., Lee, S. W., Lee, J., Lee, S., & Kang, J. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051412 · Cited by 11
Issues regarding COVID-19 in kidney transplantation in the ERA of the Omicron variant: a commentary by the ERA Descartes Working Group
Gandolfini, I., Crespo, M., Hellemans, R., Maggiore, U., Mariat, C., Mjøen, G., Oniscu, G. C., Peruzzi, L., Sever, M. Ş., Watschinger, B., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac203 · Cited by 11
Risk factors for mortality in kidney transplant recipients with COVID‐19: a single centre experience and case–control study
Choudhary, D., Kenwar, D. B., Sharma, A. K., Bhalla, A., Singh, S., Singh, M. P., Kumar, V., & Sharma, A. (2022) · BMC Nephrology · doi:10.1186/s12882-022-02821-8 · Cited by 11
Pyroptotic Patterns in Blood Leukocytes Predict Disease Severity and Outcome in COVID-19 Patients
Tang, Y., Zhang, P., Liu, Q., Cao, L., & Xu, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.888661 · Cited by 12
Safety Profile and Outcomes of Early COVID-19 Treatments in Immunocompromised Patients: A Single-Centre Cohort Study
Biscarini, S., Villa, S., Genovese, C., Tomasello, M., Tonizzo, A., Fava, M., Iannotti, N., Bolis, M., Mariani, B., Valzano, A. G., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10082002 · Cited by 11
Clinical features of COVID-19 patients with rebound phenomenon after corticosteroid therapy
Murakami, K., Sano, H., Tode, N., Tsukita, Y., Sato, K., Narita, D., Kimura, N., Matsumoto, S., Ono, Y., Iwasaki, C., et al. (2022) · BMJ Open Respiratory Research · doi:10.1136/bmjresp-2022-001332 · Cited by 11
COVID-19: Vaccines and therapeutics
Swapna, P., Birudukota, N. V. S., & Kamal, A. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128987 · Cited by 14
Early Outpatient Treatment of COVID-19: A Retrospective Analysis of 392 Cases in Italy
Cosentino, M., Vernocchi, V., Martini, S., Marino, F., Allasino, B., Bàlzola, M. A., Burigana, F., Dallari, A., Pagano, C. S. F., Palma, A., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206138 · Cited by 11
Safety and Efficacy of Combined Tixagevimab and Cilgavimab Administered Intramuscularly or Intravenously in Nonhospitalized Patients With COVID-19
Ignacio, R. B., Chew, K. W., Moser, C., Currier, J. S., Eron, J. J., Javan, A. C., Giganti, M. J., Aga, E., Gibbs, M. R. J., Kouekam, H. T., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.10039 · Cited by 12
Efficacy and Safety of Adintrevimab (ADG20) for the Treatment of High-Risk Ambulatory Patients With Mild or Moderate COVID-19: Results From a Phase 2/3, Randomized, Placebo-Controlled Trial (STAMP) Conducted During Delta Predominance and Early Emergence of Omicron
Ison, M. G., Popejoy, M. W., Evgeniev, N., Tzekova, M., Mahoney, K., Betancourt, N., Li, Y., Gupta, D., Narayan, K. M., Hershberger, E., et al. (2023) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofad279 · Cited by 11
Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review
Paltra, S., & Conrad, T. (2024) · Advances in respiratory medicine · doi:10.3390/arm92010009 · Cited by 11
Real-world Experience of Sotrovimab in High-risk, Immunocompromised COVID-19 Patients
Birk, N. K., Jain, S., Massoud, L., Ramesh, D., Monday, L., Muma, B. K., Williams, J., Alangaden, G. J., & Ramesh, M. S. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac282 · Cited by 11
Tocilizumab vs. baricitinib in hospitalized severe COVID-19 patients: results from a real-world cohort
Karolyi, M., Gruebl, A., Omid, S., Saak, M., Pawelka, E., Hoepler, W., Kelani, H., Kuran, A., Laferl, H., Ott, C., et al. (2022) · Infection · doi:10.1007/s15010-022-01915-7 · Cited by 11
Treatment of Infants and Children With SARS-CoV-2 Monoclonal Antibodies: A European Case Series
Rau, C., Auer‐Hackenberg, L., Deubzer, H. E., Schwabel, E., Jaros, M., Diederichs, A., Lehrnbecher, T., Holm, M., von Linstow, M., Martin, L., et al. (2022) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000003773 · Cited by 12
Effectiveness of vaccination against SARS-CoV-2 and the need for alternative preventative approaches in immunocompromised individuals: a narrative review of systematic reviews
Tan, T. T., Ng, H. J., Young, B. E., Khan, B. A., Shetty, V., Azmi, N. A., & Clissold, S. (2023) · Expert Review of Vaccines · doi:10.1080/14760584.2023.2191716 · Cited by 11
Sustainable Stability-Indicating spectra manipulations for the concurrent quantification of a novel Anti-COVID-19 drug and its active Metabolite: Green profile assessment
Fawzy, M. G., & Kamel, E. B. (2023) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2023.122911 · Cited by 11
Tixagevimab-cilgavimab as an Early Treatment for COVID-19 in Kidney Transplant Recipients
Benotmane, I., Olagne, J., Gautier-Vargas, G., Cognard, N., Heibel, F., Braun-Parvez, L., Keller, N., Martzloff, J., Perrin, P., Pszczolinski, R., et al. (2023) · Transplantation · doi:10.1097/tp.0000000000004655 · Cited by 11
Monoclonal Antibodies against SARS-CoV-2: Potential Game-Changer Still Underused
Gentile, I., Maraolo, A. E., Buonomo, A. R., Nobile, M., Piscitelli, P., Miani, A., & Moriello, N. S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182111159 · Cited by 10
Coronavirus Disease 2019 Vaccinations in Patients With Chronic Liver Disease and Liver Transplant Recipients: An Update
Sripongpun, P., Pinpathomrat, N., Bruminhent, J., & Kaewdech, A. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.924454 · Cited by 10
Clinical efficacy and safety of SARS-CoV-2-neutralizing monoclonal antibody in patients with COVID-19: A living systematic review and meta-analysis
Yu, S., Choi, M., Cheong, C., Ryoo, S., Huh, K., Yoon, Y. K., Choi, J., & Kim, S. B. (2023) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2023.07.009 · Cited by 11
Delayed Mucosal Antiviral Responses Despite Robust Peripheral Inflammation in Fatal COVID-19
Sidhu, J. K., Siggins, M. K., Liew, F., Russell, C. D., Uruchurtu, A. S. S., Davis, C., Turtle, L. C. W., Moore, S. C., Hardwick, H. E., Oosthuyzen, W., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad590 · Cited by 10
Lessons learnt from broad-spectrum coronavirus antiviral drug discovery
Bolinger, A. A., Li, J., Xie, X., Li, H., & Zhou, J. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2385598 · Cited by 11
Antiviral therapy for COVID-19 virus: A narrative review and bibliometric analysis
Mawazi, S. M., Fathima, N., Mahmood, S., & Al-Mahmood, S. M. A. (2024) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2024.09.001 · Cited by 10
Non-neutralizing antibodies to influenza A matrix-protein-2-ectodomain are broadly effective therapeutics and resistant to viral escape mutations
Kim, T., Bimler, L. H., Ronzulli, S. L., Song, A. Y., Johnson, S. K., Jones, C. A., Tompkins, S. M., & Paust, S. (2025) · Science Advances · doi:10.1126/sciadv.adx3505 · Cited by 10
Elements of Viral Outbreak Preparedness: Lessons, Strategies, and Future Directions
Hamza, I. A., Mao, K., Gao, C., Hamza, H., & Zhang, H. (2025) · Viruses · doi:10.3390/v18010050 · Cited by 11
Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection
Bavaro, D. F., Diella, L., Solimando, A. G., Cicco, S., Buonamico, E., Stasi, C., Ciannarella, M., Marrone, M., Carpagnano, F., Resta, O., et al. (2022) · Pathogens and Global Health · doi:10.1080/20477724.2021.2024030 · Cited by 10
Case report: Variant-specific pre-exposure prophylaxis of SARS-CoV-2 infection in multiple sclerosis patients lacking vaccination responses
Woopen, C., Konofalska, U., Akgün, K., & Ziemssen, T. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.897748 · Cited by 10
Vaccination efficacy in patients with chronic lymphocytic leukemia
Wang, K. Y., Shah, P., Skavla, B., Fayyaz, F., Chi, J., & Rhodes, J. M. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2133538 · Cited by 10
Bebtelovimab for High-Risk Outpatients With Early COVID-19 in a Large US Health System
Dryden‐Peterson, S., Kim, A., Joyce, M.-R. M., Johnson, J. A., Kim, A. Y., Baden, L. R., & Woolley, A. E. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac565 · Cited by 10
Phase 2 Safety and Antiviral Activity of SAB-185, a Novel Polyclonal Antibody Therapy for Nonhospitalized Adults With COVID-19
Taiwo, B., Chew, K. W., Moser, C., Wohl, D. A., Daar, E. S., Li, J. Z., Greninger, A. L., Bausch, C. L., Luke, T. C., Hoover, K., et al. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad013 · Cited by 10
Content validity and psychometric properties of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus©) instrument in patients with COVID-19
Keeley, T., Satram, S., Ghafoori, P., Reyes, C. M., Birch, H. J., Raymond, K., Gelhorn, H. L., Kosinski, M. R., Saucier, C. D., Foster, A. M., et al. (2023) · Quality of Life Research · doi:10.1007/s11136-022-03336-3 · Cited by 10
Efficacy of combined COVID-19 convalescent plasma with oral RNA-dependent RNA polymerase inhibitor treatment versus neutralizing monoclonal antibody therapy in COVID-19 outpatients: a multi-center, non-inferiority, open-label randomized controlled trial (PlasMab)
Siripongboonsitti, T., Nontawong, N., Tawinprai, K., Suptawiwat, O., Soonklang, K., Poovorawan, Y., & Mahanonda, N. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.03257-23 · Cited by 10

Authors: Gupta, A., Gonzalez-Rojas, Y., Juarez, E., Crespo Casal, M., Moya, J., Falci, D. R., Sarkis, E., Solis, J., Zheng, H., Scott, N., Cathcart, A. L., Hebner, C. M., Sager, J., Mogalian, E., Tipple, C., Peppercorn, A., Alexander, E., Pang, P. S., Free, A., Brinson, C., Aldinger, M., & Shapiro, A. E.
Affiliations: William Osler Health System (CA)
From the Albion Finch Medical Centre, William Osler Health Centre, Toronto (A.G.); Optimus U (Y.G.-R.) and Florida International Medical Research (E.J.), Miami, Pines Care Research Center, Pembroke Pines (J.M.), and Sarkis Clinical Trials, Gainesville (E.S.) — all in Florida; Álvaro Cunqueiro Hospital, IIS Galicia Sur, Vigo, Spain (M.C.C.); Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil (D.R.F.); Centex Studies, McAllen (J. Solis), and Central Texas Clinical Research, Austin (C.B.) — both in Texas; Vir Biotechnology, San Francisco (H.Z., A.L.C., C.M.H., J. Sager, E.M., E.A., P.S.P., M.A.); GlaxoSmithKline, Stevenage, United Kingdom (N.S., C.T.); GlaxoSmithKline, Cambridge, MA (A.P.); Pinnacle Research Group, Anniston, AL (A.F.); and the Departments of Global Health and Medicine, University of Washington, and Fred Hutchinson Cancer Research Center, Seattle (A.E.S.).
Hospital de Clínicas de Porto Alegre (BR)
The University of Texas at Austin (US)
VIR Biotechnology (United States) (US)
GlaxoSmithKline (United Kingdom) (GB)
GlaxoSmithKline (United States) (US)
University of Washington (US)
Corresponding author: Shapiro, Adrienne E.
ORCID: Pang, Phillip S.
Shapiro, Adrienne E.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2021-11-18
Volume: 385
Issue: 21
Pages: 1941-1950
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa2107934
OpenAlex: W3208080692
Cited by: 1,086
References: 25
Citations by year: 2026: 25 · 2025: 72 · 2024: 119 · 2023: 294 · 2022: 509 · 2021: 62
FWCI: 78.13
Type: journal article
Language: en
Open access: green
doi.org
Licence: cc-by-nc-nd
www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
medRxiv (acceptedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Funders: Vir Biotechnology, Inc., in collaboration with GlaxoSmithKline
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
Keywords: sotrovimab, COVID-19 pandemic, SARS-CoV-2, neutralizing monoclonal antibodies, early treatment, disease progression, hospitalization, mortality, high-risk patients, non-hospitalized patients, presymptomatic treatment, adverse events
MeSH terms: SARS-CoV-2, COVID-19 Drug Treatment, Adult, Aged, Ambulatory Care, Double-Blind Method, Female, Hospitalization, Humans, Infusions, Intravenous, Length of Stay, Male, Middle Aged, Incidence, Disease Progression, Antibodies, Neutralizing, Intention to Treat Analysis, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks